Follitropin alfa/lutropin alfa

Drug Profile

Follitropin alfa/lutropin alfa

Alternative Names: Lutropin alfa/follitropin alfa; Pergoveris; Recombinant human follicle stimulating hormone/luteinising hormone; rh-FSH/LH

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Serono Europe
  • Developer Merck Serono Co Ltd; Serono Europe
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Luteinising hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 31 Aug 2018 Discontinued - Phase-III for Female infertility (Combination therapy) in United Kingdom, Latvia, Hungary, Germany, Czech Republic, Estonia, Sweden, Belgium, Netherlands, Denmark, Spain, Poland, Finland (SC)
  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2017 The European Commission approves a liquid version of pre-filled Pergoveris™ Pen for the treatment of Female fertility in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top